 | PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (4) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Index (4) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Board | : | 4 Index COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | |
|||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING FUNDAMENTAL | ||
|---|---|---|
| Rating EPS | 0 | |
| Rating ROA | 1 | |
| Rating EQUITY | 2 | |
| Rating ROE | 0 | |
| Rating DER | 3 | |
| Rating TOTAL | 1 | |
| MARKET CAPITALIZATION | ||
| Listed Share | 11.236.680.000 | |
| Price | Rp. 122 | |
| Capitalization | Rp. 1.370.874.960.000 | |
| OWNERSHIP | ||
| Listing Date : 16-OCT-2001 | ||
| Lokal 35,06 % | Asing 64,94 % | Lainnya 0,00 % |
| PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (4) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Index (4) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Board | : | 4 Index COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
Financial Statements
| Description | 2Q18 | 2Q19 | 2Q20 | 2Q21 | 2Q22 | 2Q23 | 2Q24 | CAGR 5Y(%) |
| Last Price | 195 | 188 | 610 | 980 | 1030 | 830 | 100 | |
| Market Cap | 104.3 B | 100.6 B | 326.4 B | 524.4 B | 551.1 B | 444.1 B | 1.1 T | 993.44 |
| BALANCE SHEET | ||||||||
| Cash | 1.1 B | 2.0 B | 8.3 B | 10.1 B | 379.2 B | 63.8 B | 649.8 B | 32390.00 |
| Total Asset | 184.8 B | 184.4 B | 201.2 B | 578.0 B | 1.2 T | 1.5 T | 6.2 T | 3262.26 |
| S.T.Borrowing | 36.3 B | 28.4 B | 30.0 B | 80.1 B | 271.0 B | 334.2 B | 2.4 T | |
| L.T.Borrowing | 37.9 B | 37.4 B | 40.8 B | 323.2 B | 776.8 B | 775.2 B | 2.4 T | |
| Total Equity | 110.6 B | 118.6 B | 130.4 B | 174.6 B | 176.4 B | 405.7 B | 1.3 T | 996.12 |
| INCOME STATEMENT | ||||||||
| Revenue | 122.9 B | 121.4 B | 121.6 B | 222.5 B | 307.1 B | 313.6 B | 407.3 B | 235.50 |
| Gross Profit | 75.2 B | 70.3 B | 77.1 B | 116.1 B | 131.3 B | 137.0 B | 146.8 B | 108.82 |
| Operating Profit | 3.7 B | 3.8 B | 8.1 B | 32.9 B | 44.6 B | 4.1 B | -53.2 B | -1500.00 |
| Net.Profit | 1.7 B | 1.8 B | 5.7 B | 11.4 B | 9.1 B | -36.7 B | -115.2 B | -6500.00 |
| EBITDA | 7.4 B | 7.5 B | 11.9 B | 36.4 B | 49.5 B | 10.2 B | -41.2 B | -649.33 |
| Interest Expense | 1.4 B | 1.4 B | 1.0 B | 18.2 B | 37.0 B | 42.4 B | 62.3 B | |
| RATIO | ||||||||
| EPS | 3.19 | 3.3 | 10.65 | 21.24 | 16.92 | -68.56 | -10.29 | -411.82 |
| PER | 61.13 x | 56.97 x | 57.28 x | 46.14 x | 60.87 x | -12.11 x | -9.72 x | |
| BVPS | 206.63 | 221.56 | 243.75 | 326.33 | 329.66 | 758.13 | 120.14 | |
| PBV | 0.94 x | 0.85 x | 2.50 x | 3.00 x | 3.12 x | 1.09 x | 0.83 x | |
| ROA | 0.0092 | 0.0096 | 0.0283 | 0.0197 | 0.0074 | -0.0242 | -0.0187 | -294.79 |
| ROE | 0.0154 | 0.0149 | 0.0437 | 0.0651 | 0.0513 | -0.0904 | -0.0853 | -672.48 |
| EV/EBITDA | 23.98 | 22.05 | 32.81 | 25.21 | 24.65 | 145.35 | -128.19 | |
| Debt/Equity | 0.67 | 0.56 | 0.54 | 2.31 | 5.94 | 2.73 | 3.56 | |
| Debt/TotalCap | 0.4 | 0.36 | 0.35 | 0.7 | 0.86 | 0.73 | 0.78 | |
| Debt/EBITDA | 10.03 | 8.83 | 5.97 | 11.08 | 21.18 | 108.24 | -116.7 | |
| EBITDA/IntExps | 5.23 | 5.21 | 11.82 | 2 | 1.34 | 0.24 | -0.66 | -112.67 |
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | |
|||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| MARKET CAPITALIZATION | ||
| Listed Share | 11.236.680.000 | |
| Price | Rp. 122 | |
| Capitalization | Rp. 1.371 B. | |
| OWNERSHIP | ||
| Listing Date : 16-OCT-2001 | ||
| Lokal 35,06 % | Asing 64,94 % | Lainnya 0,00 % |
| RATING FUNDAMENTAL | ||
|---|---|---|
| Rating EPS | 0 | |
| Rating ROA | 1 | |
| Rating EQUITY | 2 | |
| Rating ROE | 0 | |
| Rating DER | 3 | |
| Rating TOTAL | 1 | |
RETURN ON ASSET
| PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | PYFA - Pyridam Farma Tbk | |
| Sector | : | Healthcare | ||
| Sub Sector | : | Pharmaceuticals and Health Care Research | ||
| Industry | : | Pharmaceuticals | ||
| Sub Industry | : | Pharmaceuticals | ||
| Index (4) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Index (4) | : | COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Board | : | 4 Index COMPOSITE, IDXSMC-COM, IDXHEALTH, DBX | ||
| Fasilitas Marjin | : | Saham yang tidak dapat diperdagangkan dengan menggunakan fasilitas marjin | ||
| Corporate Action | : | - | ||
| TIME PERIOD : 09-09-2024 | |||
| Close | 122 | Prev Close | 128 |
| Change | -6 (-4.9%) | Range | 120-130 |
| Bid | 122 | Offer | 123 |
| Bid Volume | 124500 | Offer Volume | 428100 |
| Frequency | 3748 | Value Rp.: 13.749.128.000 | |
| RETURN ON ASSET | |||||
|---|---|---|---|---|---|
| Benchmark to Others : | |||||
| A Exceptional | |||||
| B Excellent | |||||
| C Very Good | |||||
| D Good | |||||
| E Fair | |
||||
| F Poor | |||||
| RATIO (%) | ≤ 0 |
0-0.4 | 0.4- 1.7 |
1.7- 3.6 |
> 3.6 |
| RATING & BTO MATRIX | ||||||
|---|---|---|---|---|---|---|
| Benchmark to Others : | ||||||
| A Exceptional | ||||||
| B Excellent | ||||||
| C Very Good | ||||||
| D Good | ||||||
| E Fair | |
|||||
| F Poor | ||||||
| RATING | ||||||
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
| RATING | 0 | 1 | 2 | 3 | 4 | 5 |
